Genomic Health, Inc. (GHDX)
(Delayed Data from NSDQ)
$67.55 USD
+1.67 (2.53%)
Updated May 3, 2019 04:00 PM ET
After-Market: $67.63 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$67.55 USD
+1.67 (2.53%)
Updated May 3, 2019 04:00 PM ET
After-Market: $67.63 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Zacks.com featured highlights: Cabot Oil & Gas, Cardiovascular Systems, Fortress Transportation and Infrastructure, Genomic Health and Par Pacific Holdings
by Zacks Equity Research
Zacks.com featured highlights: Cabot Oil & Gas, Cardiovascular Systems, Fortress Transportation and Infrastructure, Genomic Health and Par Pacific Holdings
A Company's First Profit Can Mean Big Profits to Investors
by Kevin Matras
Kevin Matras screens for companies showing their 'first profit' and explains why they are ones to watch. Highlighted stocks include COG, CSII, FTAI, GHDX and PARR.
Genomic Health's GPS Predicts Metastatic Prostate Cancer
by Zacks Equity Research
Genomic Health, Inc. (GHDX), a global cancer company, recently unveiled positive results regarding Oncotype DX Genomic Prostate Score (GPS).
Genomic Health's Cancer Test Business Strong, Expenses High
by Zacks Equity Research
On Mar 20, we issued an updated research report on Redwood City, CA-based Genomic Health Inc. (GHDX), a leading global cancer company with a focus on advanced molecular diagnostics.
Genomic Health (GHDX) Up 2.1% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Genomic Health (GHDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Genomic Health's Breast Recurrence Test Data Encouraging
by Zacks Equity Research
Genomic Health, Inc. (GHDX), a leading molecular diagnostics company, recently presented results from 15 Oncotype DX Breast Recurrence Score studies.
Genomic Health (GHDX) Earnings Surpass Estimates in Q4
by Zacks Equity Research
Genomic Health, Inc. (GHDX) reported fourth-quarter 2016 earnings per share of 4 cents, reflecting an improvement from the year-ago quarter's loss figure of 8 cents.
Genomic Health Posts Impressive Data for Oncotype DX Test
by Zacks Equity Research
Genomic Health Inc. (GHDX) recently unveiled positive findings of its Oncotype DX test in individualizing breast cancer treatment decisions for patients at various stages of the disease.
Will Endopredict Win Myriad's (MYGN) Genomic Testing War?
by Zacks Equity Research
Myriad Genetics (MYGN) released favorable study results demonstrating the superiority of EndoPredict test over Oncotype Dx on long-term recurrence of breast cancer.
Genomic Health: Cancer Test Business Strong, Q3 Dismal
by Zacks Equity Research
On Dec 6, we issued an updated research report on Redwood City, CA-based Genomic Health Inc. (GHDX).